Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...
Zacks.com on MSN23h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical HoldAmgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback